These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 3134388

  • 1. Vaginal progesterone administration before ovulation induction with exogenous gonadotropins in polycystic ovarian syndrome.
    Buckler HM, Phillips SE, Cameron IT, Healy DL, Burger HG.
    J Clin Endocrinol Metab; 1988 Aug; 67(2):300-6. PubMed ID: 3134388
    [Abstract] [Full Text] [Related]

  • 2. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
    Christman GM, Randolph JF, Kelch RP, Marshall JC.
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
    [Abstract] [Full Text] [Related]

  • 3. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M, Campaniello E, Michelacci L, Pareschi A, Ferrari P, Bolelli G, Flamigni C.
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [Abstract] [Full Text] [Related]

  • 4. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC.
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [Abstract] [Full Text] [Related]

  • 5. Luteal function following ovulation induction in polycystic ovary syndrome patients using exogenous gonadotrophins in combination with a gonadotrophin-releasing hormone agonist.
    Donderwinkel PF, Schoot DC, Pache TD, de Jong FH, Hop WC, Fauser BC.
    Hum Reprod; 1993 Dec; 8(12):2027-32. PubMed ID: 8150898
    [Abstract] [Full Text] [Related]

  • 6. Vaginal progesterone administration in physiological doses normalizes raised luteinizing hormone levels in patients with polycystic ovarian syndrome.
    Buckler HM, Bangah M, Healy DL, Burger HG.
    Gynecol Endocrinol; 1992 Dec; 6(4):275-82. PubMed ID: 1492584
    [Abstract] [Full Text] [Related]

  • 7. Serum inhibin levels in polycystic ovary syndrome: basal levels and response to luteinizing hormone-releasing hormone agonist and exogenous gonadotropin administration.
    Buckler HM, McLachlan RI, MacLachlan VB, Healy DL, Burger HG.
    J Clin Endocrinol Metab; 1988 Apr; 66(4):798-803. PubMed ID: 3126215
    [Abstract] [Full Text] [Related]

  • 8. The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the menstrual cycle.
    Nippoldt TB, Reame NE, Kelch RP, Marshall JC.
    J Clin Endocrinol Metab; 1989 Jul; 69(1):67-76. PubMed ID: 2499593
    [Abstract] [Full Text] [Related]

  • 9. [Ovulation induction with pulsatile gonadotropin-releasing hormone and continuous human menopausal gonadotropin in polycystic ovarian disease].
    Kuroda G.
    Nihon Naibunpi Gakkai Zasshi; 1987 Mar 20; 63(3):247-59. PubMed ID: 3111899
    [Abstract] [Full Text] [Related]

  • 10. Characterization of corpora lutea in monkeys after superovulation with human menopausal gonadotropin or follicle-stimulating hormone.
    Stouffer RL, Hodgen GD, Graves PE, Danforth DR, Eyster KM, Ottobre JS.
    J Clin Endocrinol Metab; 1986 May 20; 62(5):833-9. PubMed ID: 3007556
    [Abstract] [Full Text] [Related]

  • 11. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J, De Vits A, Joostens M, Van Royen E.
    Hum Reprod; 1995 Jan 20; 10(1):56-62. PubMed ID: 7745071
    [Abstract] [Full Text] [Related]

  • 12. The importance of luteinizing hormone in the control of inhibin and progesterone secretion by the human corpus luteum.
    McLachlan RI, Cohen NL, Vale WW, Rivier JE, Burger HG, Bremner WJ, Soules MR.
    J Clin Endocrinol Metab; 1989 Jun 20; 68(6):1078-85. PubMed ID: 2498381
    [Abstract] [Full Text] [Related]

  • 13. [Endocrine evaluation of induction of ovulation with pulsatile and continuous administration of human menopausal gonadotropin (hMG) in anovulatory women].
    Masaoka K, Kitazawa M, Niibe T, Kumasaka T.
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jan 20; 38(1):73-80. PubMed ID: 3081669
    [Abstract] [Full Text] [Related]

  • 14. Regulation of ovarian follicular and luteal function during treatment with exogenous gonadotropins in anovulatory infertility.
    Yuen BH, Sy L, Cannon W.
    Am J Obstet Gynecol; 1981 Jul 15; 140(6):629-35. PubMed ID: 6167169
    [Abstract] [Full Text] [Related]

  • 15. Ovulation induction in clomiphene-resistant anovulatory women: differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone.
    Hoffman DI, Lobo RA, Campeau JD, Tsai HM, Holmberg EA, Ono T, Frederick JJ, Platt LD, diZerega GS.
    J Clin Endocrinol Metab; 1985 May 15; 60(5):922-7. PubMed ID: 3920235
    [Abstract] [Full Text] [Related]

  • 16. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
    Liu JH, Garzo G, Morris S, Stuenkel C, Ulmann A, Yen SS.
    J Clin Endocrinol Metab; 1987 Dec 15; 65(6):1135-40. PubMed ID: 2824550
    [Abstract] [Full Text] [Related]

  • 17. Serum follicle-stimulating and luteinizing hormone and progesterone in single and multiple gestations following induction of ovulation.
    Fogel M, Rubin BL, Ossowski R.
    Am J Obstet Gynecol; 1972 Mar 15; 112(5):629-39. PubMed ID: 5059593
    [Abstract] [Full Text] [Related]

  • 18. Decreased follicular phase gonadotropin secretion is associated with impaired estradiol and progesterone secretion during the follicular and luteal phases in normally menstruating women.
    Schweiger U, Laessle RG, Tuschl RJ, Broocks A, Krusche T, Pirke KM.
    J Clin Endocrinol Metab; 1989 May 15; 68(5):888-92. PubMed ID: 2497129
    [Abstract] [Full Text] [Related]

  • 19. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG, Liu J, Ulmann A, Baulieu E, Yen SS.
    J Clin Endocrinol Metab; 1988 Mar 15; 66(3):508-17. PubMed ID: 2832438
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT, Ohlinger R.
    Eur J Obstet Gynecol Reprod Biol; 2006 May 01; 126(1):87-92. PubMed ID: 16377065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.